BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer

Sarah Lidagoster, Reuben Ben-David, Benjamin De Leon, John P. Sfakianos

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Bladder cancer is a heterogeneous disease. Treatment decisions are mostly decided based on disease stage (non-muscle invasive or muscle invasive). Patients with muscle-invasive disease will be offered a radical treatment combined with systemic therapy, while in those with non-muscle-invasive disease, an attempt to resect the tumor endoscopically will usually be followed by different intravesical instillations. The goal of intravesical therapy is to decrease the recurrence and/or progression of the tumor. In the current landscape of bladder cancer treatment, BCG is given intravesically to induce an inflammatory response and recruit immune cells to attack the malignant cells and induce immune memory. While the response to BCG treatment has changed the course of bladder cancer management and spared many “bladders”, some patients may develop BCG-unresponsive disease, leaving radical surgery as the best choice of curative treatment. As a result, a lot of effort has been put into identifying novel therapies like systemic pembrolizumab and Nadofaragene-Firadenovac to continue sparing bladders if BCG is ineffective. Moreover, recent logistic issues with BCG production caused a worldwide BCG shortage, re-sparking interest in alternative BCG treatments including mitomycin C, sequential gemcitabine with docetaxel, and others. This review encompasses both the historic and current role of BCG in the treatment of non-muscle-invasive bladder cancer, revisiting BCG alternative therapies and reviewing the novel therapeutics that were approved for the BCG-unresponsive stage or are under active investigation.

Original languageEnglish
Pages (from-to)1063-1078
Number of pages16
JournalCurrent Oncology
Volume31
Issue number2
DOIs
StatePublished - Feb 2024

Keywords

  • BCG
  • BCG failure
  • bladder cancer
  • intravesical therapy

Fingerprint

Dive into the research topics of 'BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer'. Together they form a unique fingerprint.

Cite this